Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan 23:7:7.
doi: 10.1186/1750-1172-7-7.

Novel C16orf57 mutations in patients with Poikiloderma with Neutropenia: bioinformatic analysis of the protein and predicted effects of all reported mutations

Affiliations

Novel C16orf57 mutations in patients with Poikiloderma with Neutropenia: bioinformatic analysis of the protein and predicted effects of all reported mutations

Elisa A Colombo et al. Orphanet J Rare Dis. .

Abstract

Background: Poikiloderma with Neutropenia (PN) is a rare autosomal recessive genodermatosis caused by C16orf57 mutations. To date 17 mutations have been identified in 31 PN patients.

Results: We characterize six PN patients expanding the clinical phenotype of the syndrome and the mutational repertoire of the gene. We detect the two novel C16orf57 mutations, c.232C>T and c.265+2T>G, as well as the already reported c.179delC, c.531delA and c.693+1G>T mutations. cDNA analysis evidences the presence of aberrant transcripts, and bioinformatic prediction of C16orf57 protein structure gauges the mutations effects on the folded protein chain. Computational analysis of the C16orf57 protein shows two conserved H-X-S/T-X tetrapeptide motifs marking the active site of a two-fold pseudosymmetric structure recalling the 2H phosphoesterase superfamily. Based on this model C16orf57 is likely a 2H-active site enzyme functioning in RNA processing, as a presumptive RNA ligase. According to bioinformatic prediction, all known C16orf57 mutations, including the novel mutations herein described, impair the protein structure by either removing one or both tetrapeptide motifs or by destroying the symmetry of the native folding.Finally, we analyse the geographical distribution of the recurrent mutations that depicts clusters featuring a founder effect.

Conclusions: In cohorts of patients clinically affected by genodermatoses with overlapping symptoms, the molecular screening of C16orf57 gene seems the proper way to address the correct diagnosis of PN, enabling the syndrome-specific oncosurveillance. The bioinformatic prediction of the C16orf57 protein structure denotes a very basic enzymatic function consistent with a housekeeping function. Detection of aberrant transcripts, also in cells from PN patients carrying early truncated mutations, suggests they might be translatable. Tissue-specific sensitivity to the lack of functionally correct protein accounts for the main cutaneous and haematological clinical signs of PN patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Clinical findings of four differently aged PN patients. Panel A refers to the US patient (#25); B, C and D to the Turkish patients #16, #17a and #26, respectively. Patient #25, the youngest in our cohort shows an erythroderma characterized by background erythema and islands of relative sparing on face and legs (A1, A2) and distal onycholysis of fingers and toes (A3, A4). Patient #16 face: poikiloderma and carious teeth are well apparent (B1). Poikiloderma is also visible on the trunk and arm (B2). Pachyonychia of the toes is shown (B3). Facial view of patients #17a and #26 demonstrating prominent forehead, saddle nose and long philtrum (C1, D1); poikiloderma is evident on the face and on the ear helix too (C1) and forearm (D2). Plantar hyperkeratosis (C2) and nail thickening (C3) can be seen. Severe malformation of hands and feet with unhealing ulcers and marked nail dystrophy (D2, D3).
Figure 2
Figure 2
Pedigrees of index cases and genomic and cDNA characterisation of their C16orf57 homozygous mutations. Pedigrees of patients #25 (A), #16 (B), #17a (C), #21 (D), #26 (E) and #11 (F). Arrows indicate index cases. Direct sequencing of genomic DNA shows homozygous mutations in all cases: c.693+1G>T affecting the IVS6 donor splice site in patient #25 (G), c.531delA in both patients #16 and #17a (H), nonsense c.232C>T in patient #21 (I), c.265+2T>G affecting the IVS2 donor splice site in patient #26 (J) and c.179delC in patient #11 (K). L, M, N show RT-PCR products from patients #17a, #21 and #26, respectively. C+ indicates the positive control with the cDNA source from a healthy individual; C- indicates the negative control with no cDNA added to the reaction; M indicates the molecular weight markers (Generuler DNA ladder mix 100 bp-Fermentas). O, P,Q the corresponding sequencing of mutant transcripts.
Figure 3
Figure 3
Overview of recurrent C16orf57 mutations. A) Schematic representation of the C16orf57 gene with all sequence alterations so far identified. B) World map of six recurrent C16orf57 mutations with geographical distribution. Each bullet represents one tested PN patient. A specific colour is assigned to every mutant allele. Bicolour bullets highlight compound heterozygous patients.
Figure 4
Figure 4
Structural model of C16orf57 protein. A) Predicted 2H phosphoesterase family fold of human C16orf57, built by MODELLER [20] from the 1VGJ template structure (HHpred match probability of 99.9, E-value 2.9×10-29). Cartoon form with the chain colour-ramped from N-terminal residue 80 (dark blue) to C-terminal residue 265 (red); β-strands are labelled A-H and α-helices numbered 1-4. B) The two α+β lobes form an active site groove marked by the signature 2H motifs. Side chains are shown for the catalytic H120xS122 and H208xS210 residues. The flattened chain topology of human C16orf57 shows the structural repeats (boxed) and active site motifs that characterize the 2H phosphoesterase fold family. Identical labels and colours are drawn from the structural model in A and B.
Figure 5
Figure 5
Structural implications of C16orf57 mutations in PN patients. Predicted disruption of protein structure caused by 19 C16orf57 mutations (references in the first column). The N- and C-terminal sequence repeats detected by HHrep are encoded by similar exon arrays (exons 2-4 and 5-7, respectively). The correspondence between gene exons and protein domains (using the topology map of Figure 4 with similar colours and labels) is pointed out focusing on the two H-X-S motifs (grey vertical bars) that form the C16orf57 catalytic site. The top eight mutations lead to loss of both H-X-S motifs as they predict early truncation by a stop codon (c.232C>T, c.243G>A, c.258T>A and c.267T>A), frameshift (c.176_177delGG, c.179delC) or missplicing leading to frameshift (c.265+2T>G, c.266-1G>A). Six subsequent mutations terminate the protein chain before the second H-X-S motif: they include nonsense c.415C>T and c.541C>T, frameshift c.489_492del4, c.496delA and c.531delA and splice site mutation c.504-2A>C. Two mutations lead to the loss of the second H-X-S domain by inframe exon 6 skipping caused by frameshift, c.683_693+1del12, or missplicing, c.693+1G>T. Splicing c.450-2A>G and c.502A>G mutations should maintain both the key motifs, but due to inframe exon 4 skipping the protein loses a critical structural element and likely can not fold properly. Lastly, the c.673C>T stop mutation predicts a shorter chain endowed with both catalytic motifs, but unable to complete the active structure. Prediction of the effects of the different mutations is made more complex by the homozygous versus the heterozygous state. Black arrowheads indicate mutations found in the homozygous state while red arrowheads those found in the heterozygous state; the colour-code of the # symbol is according to the partnership.

Similar articles

Cited by

References

    1. Clericuzio C, Hoyme HE, Asse JM. Immune deficient poikiloderma: a new genodermatosis. AJHG. 1991;49(Suppl):A661.
    1. Wang LL, Gannavarapu A, Clericuzio CL, Erickson RP, Irvine AD, Plon SE. Absence of RECQL4 mutations in Poikiloderma with Neutropenia in Navajo and Non-Navajo patients. A J Med Genet A. 2003;118A:299–301. doi: 10.1002/ajmg.a.10057. - DOI - PubMed
    1. Van Hove JLK, Jaeken J, Proesmans M, De Boeck K, Minner K, Matthijs G, Verbeken E, Demunter A, Boogaerts M. Clericuzio type Poikiloderma With Neutropenia is distinct from Rothmund-Thomson syndrome. A J Med Genet A. 2005;132A:152–158. doi: 10.1002/ajmg.a.30430. - DOI - PubMed
    1. Mostefai R, Morice-Picard F, Boralevi F, Sautarel M, Lacombe D, Stasia MJ, McGrath J, Taïeb A. Poikiloderma with neutropenia, Clericuzio type, in a family from Morocco. Am J Med Genet. 2008;146A:2762–2769. doi: 10.1002/ajmg.a.32524. - DOI - PubMed
    1. Concolino D, Roversi G, Muzzi GL, Sestito S, Colombo EA, Volpi L, Larizza L, Strisciuglio P. Clericuzio type Poikiloderma with Neutropenia Syndrome in three sibs with mutations in the C16orf57 gene: delineation of the phenotype. Am J Med Genet A. 2010;152A:2588–2594. doi: 10.1002/ajmg.a.33600. - DOI - PubMed

Publication types